Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.

Abstract

PURPOSE ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) boosted with RTV 100 mg (FPV/r100) or with RTV 200 mg (FPV/r200) daily. METHODS this 24-week, open-label… (More)
DOI: 10.1310/hct1105-239

Topics

Cite this paper

@article{Cohen2010SimilarVA, title={Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.}, author={Calvin J. Cohen and Edwin Dejesus and Anthony LaMarca and Benjamin Young and Linda H. Y. Yau and L. D. Patel and Cindy L Vavro and Mary Beth Wire and Paul G Wannamaker and Mark S. Shaefer}, journal={HIV clinical trials}, year={2010}, volume={11 5}, pages={239-47} }